Senseonics Prices Public Offering of 8 Million Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SENS?
Source: Newsfilter
- Offering Details: Senseonics announced a public offering of 8 million shares at $5.00 per share, expecting gross proceeds of $80 million, indicating a proactive approach to capital raising in the market.
- Pre-Funded Warrant Structure: The offering includes pre-funded warrants for certain investors at $4.999 per share, enhancing investor participation while reducing overall financing costs.
- Use of Proceeds: The company intends to utilize the proceeds for the ongoing launch of Eversense 365 and product development, highlighting its commitment to market penetration and competitive positioning.
- Underwriter Selection: TD Cowen and Barclays are acting as joint book-running managers, reflecting strategic considerations in underwriter selection to ensure a smooth offering process and maximize financing outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SENS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SENS
Wall Street analysts forecast SENS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.425
Low
9.00
Averages
18.70
High
31.00
Current: 6.425
Low
9.00
Averages
18.70
High
31.00
About SENS
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SENSEONICS HOLDINGS INC - REVEALS PRICING FOR 8 MILLION SHARE OFFERING AT $5.00 PER SHARE AND 8 MILLION PRE-FUNDED WARRANTS AT $4.999 PER SHARE
- Announcement of Share Offering: Sensonics Holdings has announced a pricing of an 8 million share offering at $5.00 per share.
- Pre-Funded Warrants Pricing: The company is also offering 8 million pre-funded warrants priced at $4.99 per share.
See More
Senseonics Prices Public Offering of 8 Million Shares
- Offering Details: Senseonics announced a public offering of 8 million shares at $5.00 per share, expecting gross proceeds of $80 million, indicating a proactive approach to capital raising in the market.
- Pre-Funded Warrant Structure: The offering includes pre-funded warrants for certain investors at $4.999 per share, enhancing investor participation while reducing overall financing costs.
- Use of Proceeds: The company intends to utilize the proceeds for the ongoing launch of Eversense 365 and product development, highlighting its commitment to market penetration and competitive positioning.
- Underwriter Selection: TD Cowen and Barclays are acting as joint book-running managers, reflecting strategic considerations in underwriter selection to ensure a smooth offering process and maximize financing outcomes.
See More
Senseonics Prices Public Offering of 8 Million Shares
- Offering Details: Senseonics announced a public offering of 8 million shares at $5.00 per share, expecting gross proceeds of $80 million, reflecting the company's proactive financing strategy in the capital markets.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for certain investors, allowing them to purchase 8 million shares at $4.999 each, enhancing investor participation and reducing financing costs.
- Use of Proceeds: The net proceeds from this offering will fund the ongoing launch of Eversense 365, continued product pipeline development, and general corporate purposes, indicating the company's strategic focus on future growth.
- Underwriter Selection: TD Cowen and Barclays are acting as joint book-running managers, with Mizuho and Lake Street as bookrunners, showcasing the company's professionalism and market credibility in selecting underwriters.
See More
Senseonics Launches Underwritten Public Offering of Common Stock
- Public Offering Initiated: Senseonics has officially commenced an underwritten public offering of common stock and pre-funded warrants, aiming to raise funds to support the operations and growth of its implantable continuous glucose monitoring systems for diabetes management.
- Investor Options: Certain investors may receive pre-funded warrants instead of common stock, which will not be exchange-listed, indicating the company's flexibility in its financing structure.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase up to 15% additional shares, a strategy designed to enhance market acceptance and liquidity of the offering.
- Clear Use of Proceeds: The proceeds from this public offering are expected to support the ongoing operations and growth in the diabetes management sector, reflecting Senseonics' confidence and strategic planning for future market expansion.
See More
Senseonics Launches Eversense 365 System in Europe
- Product Innovation: Senseonics has launched the Eversense 365 system, the world's first continuous glucose monitor designed to last a full year, with a sensor that provides 12 months of uninterrupted glucose readings, doubling the lifespan of the previous six-month Eversense E3 system and significantly reducing the burden of daily diabetes management for patients.
- Market Expansion: The system has begun its commercial rollout in Sweden, with Germany, Spain, and Italy set to follow in the coming weeks, potentially reaching over 30 million patients across Europe and significantly expanding the company's addressable market.
- Technological Advantages: The Eversense 365 system offers weekly calibration instead of daily, reducing routine maintenance needs, and features a removable smart transmitter that allows users to temporarily take it off without wasting a sensor, while also providing high accuracy with fewer false alerts, particularly during sleep.
- Strategic Integration: The CEO of Senseonics stated that the European launch represents a major milestone in the company's transition to a fully integrated commercial organization, further strengthening its position in the diabetes-tech ecosystem, especially with the integration of Eversense 365 with Sequel Med Tech's twiist automated insulin delivery system.
See More
Eversense 365 Launches in Europe, Doubling Sensor Lifespan to One Year
- Product Launch: The Eversense 365 has been launched in Sweden, with upcoming rollouts in Germany, Spain, and Italy, marking a significant expansion into the European market and potentially increasing the total addressable market by over 30 million patients.
- Extended Sensor Lifespan: The next-generation Eversense 365 doubles the sensor lifespan from six months to one year, significantly reducing the frequency of replacements for patients, thereby enhancing user experience and satisfaction.
- Technological Advantages: Eversense 365 requires calibration only once a week, greatly simplifying daily management for users and minimizing the inconvenience caused by frequent calibrations, allowing patients to focus more on diabetes management.
- Market Outlook: Senseonics CEO Tim Goodnow stated that this launch represents a major breakthrough in diabetes technology, expected to drive the company's transition to a fully commercial organization and enhance its competitiveness in the global diabetes management market.
See More
SENSEONICS HOLDINGS INC - REVEALS PRICING FOR 8 MILLION SHARE OFFERING AT $5.00 PER SHARE AND 8 MILLION PRE-FUNDED WARRANTS AT $4.999 PER SHARE
- Announcement of Share Offering: Sensonics Holdings has announced a pricing of an 8 million share offering at $5.00 per share.
- Pre-Funded Warrants Pricing: The company is also offering 8 million pre-funded warrants priced at $4.99 per share.
See More
Senseonics Prices Public Offering of 8 Million Shares
- Offering Details: Senseonics announced a public offering of 8 million shares at $5.00 per share, expecting gross proceeds of $80 million, indicating a proactive approach to capital raising in the market.
- Pre-Funded Warrant Structure: The offering includes pre-funded warrants for certain investors at $4.999 per share, enhancing investor participation while reducing overall financing costs.
- Use of Proceeds: The company intends to utilize the proceeds for the ongoing launch of Eversense 365 and product development, highlighting its commitment to market penetration and competitive positioning.
- Underwriter Selection: TD Cowen and Barclays are acting as joint book-running managers, reflecting strategic considerations in underwriter selection to ensure a smooth offering process and maximize financing outcomes.
See More
Senseonics Prices Public Offering of 8 Million Shares
- Offering Details: Senseonics announced a public offering of 8 million shares at $5.00 per share, expecting gross proceeds of $80 million, reflecting the company's proactive financing strategy in the capital markets.
- Pre-Funded Warrant Arrangement: The offering includes pre-funded warrants for certain investors, allowing them to purchase 8 million shares at $4.999 each, enhancing investor participation and reducing financing costs.
- Use of Proceeds: The net proceeds from this offering will fund the ongoing launch of Eversense 365, continued product pipeline development, and general corporate purposes, indicating the company's strategic focus on future growth.
- Underwriter Selection: TD Cowen and Barclays are acting as joint book-running managers, with Mizuho and Lake Street as bookrunners, showcasing the company's professionalism and market credibility in selecting underwriters.
See More
Senseonics Launches Underwritten Public Offering of Common Stock
- Public Offering Initiated: Senseonics has officially commenced an underwritten public offering of common stock and pre-funded warrants, aiming to raise funds to support the operations and growth of its implantable continuous glucose monitoring systems for diabetes management.
- Investor Options: Certain investors may receive pre-funded warrants instead of common stock, which will not be exchange-listed, indicating the company's flexibility in its financing structure.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase up to 15% additional shares, a strategy designed to enhance market acceptance and liquidity of the offering.
- Clear Use of Proceeds: The proceeds from this public offering are expected to support the ongoing operations and growth in the diabetes management sector, reflecting Senseonics' confidence and strategic planning for future market expansion.
See More
Senseonics Launches Eversense 365 System in Europe
- Product Innovation: Senseonics has launched the Eversense 365 system, the world's first continuous glucose monitor designed to last a full year, with a sensor that provides 12 months of uninterrupted glucose readings, doubling the lifespan of the previous six-month Eversense E3 system and significantly reducing the burden of daily diabetes management for patients.
- Market Expansion: The system has begun its commercial rollout in Sweden, with Germany, Spain, and Italy set to follow in the coming weeks, potentially reaching over 30 million patients across Europe and significantly expanding the company's addressable market.
- Technological Advantages: The Eversense 365 system offers weekly calibration instead of daily, reducing routine maintenance needs, and features a removable smart transmitter that allows users to temporarily take it off without wasting a sensor, while also providing high accuracy with fewer false alerts, particularly during sleep.
- Strategic Integration: The CEO of Senseonics stated that the European launch represents a major milestone in the company's transition to a fully integrated commercial organization, further strengthening its position in the diabetes-tech ecosystem, especially with the integration of Eversense 365 with Sequel Med Tech's twiist automated insulin delivery system.
See More
Eversense 365 Launches in Europe, Doubling Sensor Lifespan to One Year
- Product Launch: The Eversense 365 has been launched in Sweden, with upcoming rollouts in Germany, Spain, and Italy, marking a significant expansion into the European market and potentially increasing the total addressable market by over 30 million patients.
- Extended Sensor Lifespan: The next-generation Eversense 365 doubles the sensor lifespan from six months to one year, significantly reducing the frequency of replacements for patients, thereby enhancing user experience and satisfaction.
- Technological Advantages: Eversense 365 requires calibration only once a week, greatly simplifying daily management for users and minimizing the inconvenience caused by frequent calibrations, allowing patients to focus more on diabetes management.
- Market Outlook: Senseonics CEO Tim Goodnow stated that this launch represents a major breakthrough in diabetes technology, expected to drive the company's transition to a fully commercial organization and enhance its competitiveness in the global diabetes management market.
See More
